MyAza (Azacitidine for Injection) contains Azacitidine IP, which is a pyrimidine The finished product is supplied in a sterile form for reconstitution as a. No formal clinical drug interaction studies with azacitidine have been conducted. The printed package leaflet of the medicinal product must state the name. Drug: Azacitidine – Vidaza® Oncology – Intravenous Dilution Data. (, ) – [ SEE PACKAGE INSERT FOR ADDITIONAL DETAILS]].
|Published (Last):||8 March 2015|
|PDF File Size:||14.5 Mb|
|ePub File Size:||19.20 Mb|
|Price:||Free* [*Free Regsitration Required]|
If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful. In vitro studies with human cultured hepatocytes indicate that azacitidine at concentrations of 1.
Instructions for Intravenous Administration.
Progressive hepatic coma and death have been reported in azacitidine-treated patients with extensive tumor burden due to metastatic disease, particularly in patients with hypoalbuminemia i.
Methylation of DNA is a major mechanism that regulates gene expression in cells.
No azacitidine dosage adjustment is necessary in cycle 1 in patients with renal impairment. This medication is classified as an “antimetabolite” and azqcitidine “demethylation” agent. Bone marrow suppression including anemia, neutropenia, and thrombocytopenia has been commonly reported.
Contact your health care provider within 24 hours of noticing any of the following: Hepatotoxicity may occur in patients with severe hepatic impairment. Your Name Your name is required. It is not known if azacitidine or its metabolites are secreted in human milk or if it has effects on the breast-fed infant or on milk production. Azacitidine also belongs to the category of chemotherapy called antimetabolites. Parenteral drug product should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Rotate sites for each injection thigh, abdomen, or upper arm. Preparation for Delayed Subcutaneous Administration: VIDAZA is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow.
Azacitidine has been designated an orphan drug for this indication. You will be checked regularly by your health care professional while you are taking azacitidine, to monitor side effects and check your response to packagd.
Vigorously shake or roll the vial until a uniform suspension is achieved. The authors make no claims of the accuracy of the information contained herein; and these aaacitidine doses are not a substitute for clinical judgment.
When suppressor genes are blocked, cell division becomes unregulated, allowing or promoting cancer. Immediately nisert to administration, invert the syringe 2 or 3 times and vigorously roll the syringe between the palms until a uniform, cloudy suspension is achieved. Treatment may be continued as long as the patient continues to benefit.
If it comes into contact with mucous membranes, flush thoroughly with water.
Azacitidine – Drug Information – Chemocare
Contraception requirements, infertility, male-mediated teratogenicity, pregnancy testing, reproductive risk. Specific guidelines for dosage adjustments in hepatic impairment are not available. Doses greater than 4 mL should be divided equally into 2 syringes and injected into 2 separate sites. Preparation for Immediate Subcutaneous Administration: Contact your health care provider immediatelyday or night, if you should experience any of the following symptoms: Due to the azaciyidine of serious adverse reactions including tumorigenicity in nursing infants, women should discontinue breast-feeding during azacitidine therapy and for 1 week after the last dose.
In some cancer cells, hypermethylation blocks the activity of tumor suppressor genes, which regulate cell division and differentiation to prevent malignant transformation. Females of reproductive potential azaditidine avoid pregnancy during treatment with azacitidine. Azacitidine is an anti-cancer “antineoplastic” or “cytotoxic” chemotherapy drug. Visually inspect parenteral products for particulate matter and discoloration prior to administration whenever solution and container permit.
TLS may occur despite prophylaxis with allopurinol. Azacitidine is contraindicated in patients with advanced hepatic malignancies.